SCHEMBL455181

SCHEMBL455181

COO[O]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131007 0.72
SCHEMBL27257 0.63
Methoxymethane SCHEMBL10891136 0.63
SCHEMBL16187035 0.63
Acetaldehyde SCHEMBL29598311 0.58
Hydrochloric Acid SCHEMBL102568 0.58
SCHEMBL28807216 0.58
SCHEMBL8935213 0.58
Methoxymethane SCHEMBL28382799 0.58
SCHEMBL27906098 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481558-B2 Compounds to inhibit or augment an inflammatory response CAMBRIDGE ENTERPRISE LIMITED (GB) 2013-07-09 US claimed
US-20120065401-A1 METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE CAMBRIDGE ENTERPRISE LIMITED (GB) 2012-03-15 US claimed
EP-2386565-A2 Compounds and methods to inhibit or augment an inflammatory response Cambridge Enterprise Ltd. (GB) 2011-11-16 EP claimed
US-7989466-B2 Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-02 US claimed
US-20080045557-A1 Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. 2008-02-21 US claimed
EP-1019373-A1 NOVEL HUMAN NK 3? RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI-SYNTHELABO (FR) 2000-07-19 EP claimed
WO-1997010211-A1 NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI (FR) 1997-03-20 WO claimed
US-8481558-B2 Compounds to inhibit or augment an inflammatory response CAMBRIDGE ENTERPRISE LIMITED (GB) 2013-07-09 US disclosed
US-20120065401-A1 METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE CAMBRIDGE ENTERPRISE LIMITED (GB) 2012-03-15 US disclosed
EP-2386565-A2 Compounds and methods to inhibit or augment an inflammatory response Cambridge Enterprise Ltd. (GB) 2011-11-16 EP disclosed
US-7989466-B2 Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-02 US disclosed
US-20080045557-A1 Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. 2008-02-21 US disclosed
US-7238711-B1 Compounds and methods to inhibit or augment an inflammatory response CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) 2007-07-03 US disclosed
EP-1141011-A2 COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE NEORX CORPORATION (US) 2001-10-10 EP disclosed
WO-2000042071-A2 COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) 2000-07-20 WO disclosed